Redx sells another asset to keep the lights on
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Two more patients bolster Sangamo’s haemophilia A gene therapy
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
Threats to Spinraza are mounting, but Biogen still has cards to play
Competition is looming from Novartis and Roche but the latest results from Spinraza show that Biogen still has a strong case to make for the SMA therapy.
Big cap stocks grow in first half despite M&A activity, not because of it
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
Which direction for Turning Point?
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
Merck and the pitfalls of biopharma success
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
Abbvie proves the best at getting the most out of its workers
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
G1 makes the most of trilaciclib's unclear survival benefit
G1 Therapeutics fast-tracks what it says is the first CDK4/6 inhibitor aimed at reducing chemotherapy-induced myelosuppression.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.